A novel mesenchymal epithelial transition (MET) inhibitor, CB538, relieves acquired resistance in EGFR-mutated MET-amplified non-small cell lung cancer.

一种新型间质上皮转化（MET）抑制剂CB538可缓解EGFR突变MET扩增的非小细胞肺癌的获得性耐药性